Establishment of a novel experimental model for muscle‐invasive bladder cancer using a dog bladder cancer organoid culture
In human and dogs, bladder cancer (BC) is the most common neoplasm affecting the urinary tract. Dog BC resembles human muscle‐invasive BC in histopathological characteristics and gene expression profiles, and could be an important research model for this disease. Cancer patient‐derived organoid cult...
Saved in:
| Published in | Cancer science Vol. 110; no. 9; pp. 2806 - 2821 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
John Wiley & Sons, Inc
01.09.2019
John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | In human and dogs, bladder cancer (BC) is the most common neoplasm affecting the urinary tract. Dog BC resembles human muscle‐invasive BC in histopathological characteristics and gene expression profiles, and could be an important research model for this disease. Cancer patient‐derived organoid culture can recapitulate organ structures and maintains the gene expression profiles of original tumor tissues. In a previous study, we generated dog prostate cancer organoids using urine samples, however dog BC organoids had never been produced. Therefore we aimed to generate dog BC organoids using urine samples and check their histopathological characteristics, drug sensitivity, and gene expression profiles. Organoids from individual BC dogs were successfully generated, expressed urothelial cell markers (CK7, CK20, and UPK3A) and exhibited tumorigenesis in vivo. In a cell viability assay, the response to combined treatment with a range of anticancer drugs (cisplatin, vinblastine, gemcitabine or piroxicam) was markedly different in each BC organoid. In RNA‐sequencing analysis, expression levels of basal cell markers (CK5 and DSG3) and several novel genes (MMP28, CTSE, CNN3, TFPI2, COL17A1, and AGPAT4) were upregulated in BC organoids compared with normal bladder tissues or two‐dimensional (2D) BC cell lines. These established dog BC organoids might be a useful tool, not only to determine suitable chemotherapy for BC diseased dogs but also to identify novel biomarkers in human muscle‐invasive BC. In the present study, for the 1st time, dog BC organoids were generated and several specifically upregulated organoid genes were identified. Our data suggest that dog BC organoids might become a new tool to provide fresh insights into both dog BC therapy and diagnostic biomarkers.
In the present study, we for the first time generated dog bladder cancer (BC) organoids and identified several genes specifically upregulated in the organoids. Our data suggest that dog BC organoids might become a new tool to provide new insights for both dog BC therapy and diagnostic markers. |
|---|---|
| AbstractList | In human and dogs, bladder cancer (BC) is the most common neoplasm affecting the urinary tract. Dog BC resembles human muscle-invasive BC in histopathological characteristics and gene expression profiles, and could be an important research model for this disease. Cancer patient-derived organoid culture can recapitulate organ structures and maintains the gene expression profiles of original tumor tissues. In a previous study, we generated dog prostate cancer organoids using urine samples, however dog BC organoids had never been produced. Therefore we aimed to generate dog BC organoids using urine samples and check their histopathological characteristics, drug sensitivity, and gene expression profiles. Organoids from individual BC dogs were successfully generated, expressed urothelial cell markers (CK7, CK20, and UPK3A) and exhibited tumorigenesis in vivo. In a cell viability assay, the response to combined treatment with a range of anticancer drugs (cisplatin, vinblastine, gemcitabine or piroxicam) was markedly different in each BC organoid. In RNA-sequencing analysis, expression levels of basal cell markers (CK5 and DSG3) and several novel genes (MMP28, CTSE, CNN3, TFPI2, COL17A1, and AGPAT4) were upregulated in BC organoids compared with normal bladder tissues or two-dimensional (2D) BC cell lines. These established dog BC organoids might be a useful tool, not only to determine suitable chemotherapy for BC diseased dogs but also to identify novel biomarkers in human muscle-invasive BC. In the present study, for the 1st time, dog BC organoids were generated and several specifically upregulated organoid genes were identified. Our data suggest that dog BC organoids might become a new tool to provide fresh insights into both dog BC therapy and diagnostic biomarkers.In human and dogs, bladder cancer (BC) is the most common neoplasm affecting the urinary tract. Dog BC resembles human muscle-invasive BC in histopathological characteristics and gene expression profiles, and could be an important research model for this disease. Cancer patient-derived organoid culture can recapitulate organ structures and maintains the gene expression profiles of original tumor tissues. In a previous study, we generated dog prostate cancer organoids using urine samples, however dog BC organoids had never been produced. Therefore we aimed to generate dog BC organoids using urine samples and check their histopathological characteristics, drug sensitivity, and gene expression profiles. Organoids from individual BC dogs were successfully generated, expressed urothelial cell markers (CK7, CK20, and UPK3A) and exhibited tumorigenesis in vivo. In a cell viability assay, the response to combined treatment with a range of anticancer drugs (cisplatin, vinblastine, gemcitabine or piroxicam) was markedly different in each BC organoid. In RNA-sequencing analysis, expression levels of basal cell markers (CK5 and DSG3) and several novel genes (MMP28, CTSE, CNN3, TFPI2, COL17A1, and AGPAT4) were upregulated in BC organoids compared with normal bladder tissues or two-dimensional (2D) BC cell lines. These established dog BC organoids might be a useful tool, not only to determine suitable chemotherapy for BC diseased dogs but also to identify novel biomarkers in human muscle-invasive BC. In the present study, for the 1st time, dog BC organoids were generated and several specifically upregulated organoid genes were identified. Our data suggest that dog BC organoids might become a new tool to provide fresh insights into both dog BC therapy and diagnostic biomarkers. In human and dogs, bladder cancer (BC) is the most common neoplasm affecting the urinary tract. Dog BC resembles human muscle-invasive BC in histopathological characteristics and gene expression profiles, and could be an important research model for this disease. Cancer patient-derived organoid culture can recapitulate organ structures and maintains the gene expression profiles of original tumor tissues. In a previous study, we generated dog prostate cancer organoids using urine samples, however dog BC organoids had never been produced. Therefore we aimed to generate dog BC organoids using urine samples and check their histopathological characteristics, drug sensitivity, and gene expression profiles. Organoids from individual BC dogs were successfully generated, expressed urothelial cell markers (CK7, CK20, and UPK3A) and exhibited tumorigenesis in vivo. In a cell viability assay, the response to combined treatment with a range of anticancer drugs (cisplatin, vinblastine, gemcitabine or piroxicam) was markedly different in each BC organoid. In RNA-sequencing analysis, expression levels of basal cell markers (CK5 and DSG3) and several novel genes (MMP28, CTSE, CNN3, TFPI2, COL17A1, and AGPAT4) were upregulated in BC organoids compared with normal bladder tissues or two-dimensional (2D) BC cell lines. These established dog BC organoids might be a useful tool, not only to determine suitable chemotherapy for BC diseased dogs but also to identify novel biomarkers in human muscle-invasive BC. In the present study, for the 1st time, dog BC organoids were generated and several specifically upregulated organoid genes were identified. Our data suggest that dog BC organoids might become a new tool to provide fresh insights into both dog BC therapy and diagnostic biomarkers. In human and dogs, bladder cancer (BC) is the most common neoplasm affecting the urinary tract. Dog BC resembles human muscle‐invasive BC in histopathological characteristics and gene expression profiles, and could be an important research model for this disease. Cancer patient‐derived organoid culture can recapitulate organ structures and maintains the gene expression profiles of original tumor tissues. In a previous study, we generated dog prostate cancer organoids using urine samples, however dog BC organoids had never been produced. Therefore we aimed to generate dog BC organoids using urine samples and check their histopathological characteristics, drug sensitivity, and gene expression profiles. Organoids from individual BC dogs were successfully generated, expressed urothelial cell markers (CK7, CK20, and UPK3A) and exhibited tumorigenesis in vivo. In a cell viability assay, the response to combined treatment with a range of anticancer drugs (cisplatin, vinblastine, gemcitabine or piroxicam) was markedly different in each BC organoid. In RNA‐sequencing analysis, expression levels of basal cell markers (CK5 and DSG3) and several novel genes (MMP28, CTSE, CNN3, TFPI2, COL17A1, and AGPAT4) were upregulated in BC organoids compared with normal bladder tissues or two‐dimensional (2D) BC cell lines. These established dog BC organoids might be a useful tool, not only to determine suitable chemotherapy for BC diseased dogs but also to identify novel biomarkers in human muscle‐invasive BC. In the present study, for the 1st time, dog BC organoids were generated and several specifically upregulated organoid genes were identified. Our data suggest that dog BC organoids might become a new tool to provide fresh insights into both dog BC therapy and diagnostic biomarkers. In the present study, we for the first time generated dog bladder cancer (BC) organoids and identified several genes specifically upregulated in the organoids. Our data suggest that dog BC organoids might become a new tool to provide new insights for both dog BC therapy and diagnostic markers. In human and dogs, bladder cancer ( BC ) is the most common neoplasm affecting the urinary tract. Dog BC resembles human muscle‐invasive BC in histopathological characteristics and gene expression profiles, and could be an important research model for this disease. Cancer patient‐derived organoid culture can recapitulate organ structures and maintains the gene expression profiles of original tumor tissues. In a previous study, we generated dog prostate cancer organoids using urine samples, however dog BC organoids had never been produced. Therefore we aimed to generate dog BC organoids using urine samples and check their histopathological characteristics, drug sensitivity, and gene expression profiles. Organoids from individual BC dogs were successfully generated, expressed urothelial cell markers ( CK 7, CK 20, and UPK 3A) and exhibited tumorigenesis in vivo. In a cell viability assay, the response to combined treatment with a range of anticancer drugs (cisplatin, vinblastine, gemcitabine or piroxicam) was markedly different in each BC organoid. In RNA ‐sequencing analysis, expression levels of basal cell markers ( CK 5 and DSG 3 ) and several novel genes ( MMP 28 , CTSE , CNN 3 , TFPI 2 , COL 17A1 , and AGPAT 4 ) were upregulated in BC organoids compared with normal bladder tissues or two‐dimensional (2D) BC cell lines. These established dog BC organoids might be a useful tool, not only to determine suitable chemotherapy for BC diseased dogs but also to identify novel biomarkers in human muscle‐invasive BC . In the present study, for the 1st time, dog BC organoids were generated and several specifically upregulated organoid genes were identified. Our data suggest that dog BC organoids might become a new tool to provide fresh insights into both dog BC therapy and diagnostic biomarkers. |
| Author | Masuda, Sosuke Nakagawa, Takayuki Nabeta, Rina Mizutani, Tetsuya Iwai, Satomi Hazama, Shoichi Uchide, Tsuyoshi Usui, Tatsuya Tanaka, Takaharu Kaneda, Masahiro Elbadawy, Mohamed Yamawaki, Hideyuki Tsunedomi, Ryouichi Yoshida, Toshinori Ichikawa, Ryo Katayama, Yukie Mori, Takashi Okada, Rena Noguchi, Shunsuke Shinohara, Yuta Fukushima, Ryuji Shibutani, Makoto Omatsu, Tsutomu Sasaki, Kazuaki |
| AuthorAffiliation | 4 Center for Highly Advanced Integration of Nano and Life Sciences Gifu University (G‐CHAIN) Gifu Japan 9 Laboratory of Veterinary Pathology Department of Veterinary Medicine Faculty of Agriculture Tokyo University of Agriculture and Technology Fuchu Japan 5 Department of Gastroenterological, Breast, and Endocrine Surgery Yamaguchi University Graduate School of Medicine Ube Japan 6 Department of Translational Research and Developmental Therapeutics against Cancer School of Medicine Yamaguchi University Ube Japan 11 Laboratory of Veterinary Radiology Graduate School of Life and Environmental Sciences Osaka Prefecture University Sano Japan 13 Laboratory of Veterinary Surgery Graduate School of Agricultural and Life Sciences University of Tokyo Tokyo Japan 16 Laboratory of Veterinary Pharmacology School of Veterinary Medicine Kitasato University Towada Japan 10 Research and Education Center for Prevention of Global Infectious Disease of Animals Tokyo University of Agriculture and Technology Fuch |
| AuthorAffiliation_xml | – name: 15 Laboratory of Veterinary Anatomy Department of Veterinary Medicine Faculty of Agriculture Tokyo University of Agriculture and Technology Fuchu Japan – name: 7 Department of Veterinary Surgery Faculty of Agriculture Tokyo University of Agriculture and Technology Fuchu Japan – name: 5 Department of Gastroenterological, Breast, and Endocrine Surgery Yamaguchi University Graduate School of Medicine Ube Japan – name: 2 Department of Pharmacology Faculty of Veterinary Medicine Benha University Toukh Egypt – name: 13 Laboratory of Veterinary Surgery Graduate School of Agricultural and Life Sciences University of Tokyo Tokyo Japan – name: 1 Laboratory of Veterinary Pharmacology Department of Veterinary Medicine Faculty of Agriculture Tokyo University of Agriculture and Technology Fuchu Japan – name: 10 Research and Education Center for Prevention of Global Infectious Disease of Animals Tokyo University of Agriculture and Technology Fuchu Japan – name: 16 Laboratory of Veterinary Pharmacology School of Veterinary Medicine Kitasato University Towada Japan – name: 9 Laboratory of Veterinary Pathology Department of Veterinary Medicine Faculty of Agriculture Tokyo University of Agriculture and Technology Fuchu Japan – name: 3 Laboratory of Veterinary Clinical Oncology Faculty of Applied Biological Sciences Gifu University Gifu Japan – name: 4 Center for Highly Advanced Integration of Nano and Life Sciences Gifu University (G‐CHAIN) Gifu Japan – name: 12 Laboratory of Small Animal Surgery 2 School of Veterinary Medicine Kitasato University Towada Japan – name: 11 Laboratory of Veterinary Radiology Graduate School of Life and Environmental Sciences Osaka Prefecture University Sano Japan – name: 8 Animal Medical Center Faculty of Agriculture Tokyo University of Agriculture and Technology Fuchu Japan – name: 6 Department of Translational Research and Developmental Therapeutics against Cancer School of Medicine Yamaguchi University Ube Japan – name: 14 Pet Health & Food Division Iskara Industry CO., LTD Tokyo Japan |
| Author_xml | – sequence: 1 givenname: Mohamed orcidid: 0000-0001-9368-1535 surname: Elbadawy fullname: Elbadawy, Mohamed organization: Benha University – sequence: 2 givenname: Tatsuya orcidid: 0000-0002-1818-2127 surname: Usui fullname: Usui, Tatsuya email: fu7085@go.tuat.ac.jp organization: Tokyo University of Agriculture and Technology – sequence: 3 givenname: Takashi surname: Mori fullname: Mori, Takashi organization: Gifu University (G‐CHAIN) – sequence: 4 givenname: Ryouichi orcidid: 0000-0003-4251-1936 surname: Tsunedomi fullname: Tsunedomi, Ryouichi organization: Yamaguchi University Graduate School of Medicine – sequence: 5 givenname: Shoichi orcidid: 0000-0002-5239-8570 surname: Hazama fullname: Hazama, Shoichi organization: Yamaguchi University – sequence: 6 givenname: Rina surname: Nabeta fullname: Nabeta, Rina organization: Tokyo University of Agriculture and Technology – sequence: 7 givenname: Tsuyoshi surname: Uchide fullname: Uchide, Tsuyoshi organization: Tokyo University of Agriculture and Technology – sequence: 8 givenname: Ryuji surname: Fukushima fullname: Fukushima, Ryuji organization: Tokyo University of Agriculture and Technology – sequence: 9 givenname: Toshinori surname: Yoshida fullname: Yoshida, Toshinori organization: Tokyo University of Agriculture and Technology – sequence: 10 givenname: Makoto orcidid: 0000-0003-3417-9697 surname: Shibutani fullname: Shibutani, Makoto organization: Tokyo University of Agriculture and Technology – sequence: 11 givenname: Takaharu surname: Tanaka fullname: Tanaka, Takaharu organization: Tokyo University of Agriculture and Technology – sequence: 12 givenname: Sosuke surname: Masuda fullname: Masuda, Sosuke organization: Tokyo University of Agriculture and Technology – sequence: 13 givenname: Rena surname: Okada fullname: Okada, Rena organization: Tokyo University of Agriculture and Technology – sequence: 14 givenname: Ryo surname: Ichikawa fullname: Ichikawa, Ryo organization: Tokyo University of Agriculture and Technology – sequence: 15 givenname: Tsutomu surname: Omatsu fullname: Omatsu, Tsutomu organization: Tokyo University of Agriculture and Technology – sequence: 16 givenname: Tetsuya surname: Mizutani fullname: Mizutani, Tetsuya organization: Tokyo University of Agriculture and Technology – sequence: 17 givenname: Yukie surname: Katayama fullname: Katayama, Yukie organization: Tokyo University of Agriculture and Technology – sequence: 18 givenname: Shunsuke surname: Noguchi fullname: Noguchi, Shunsuke organization: Osaka Prefecture University – sequence: 19 givenname: Satomi surname: Iwai fullname: Iwai, Satomi organization: Kitasato University – sequence: 20 givenname: Takayuki surname: Nakagawa fullname: Nakagawa, Takayuki organization: University of Tokyo – sequence: 21 givenname: Yuta surname: Shinohara fullname: Shinohara, Yuta organization: Iskara Industry CO., LTD – sequence: 22 givenname: Masahiro surname: Kaneda fullname: Kaneda, Masahiro organization: Tokyo University of Agriculture and Technology – sequence: 23 givenname: Hideyuki surname: Yamawaki fullname: Yamawaki, Hideyuki organization: Kitasato University – sequence: 24 givenname: Kazuaki surname: Sasaki fullname: Sasaki, Kazuaki organization: Tokyo University of Agriculture and Technology |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31254429$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kctu1DAUhi1URC-w4AWQJTZlkdb3JBukalQuUiUWhbXlOCdTV4492MlApS54BJ6RJ8HTKRUdCbw51jmff53f_yHaCzEAQi8pOaHlnFqTT6igtHmCDigXbVUTovbu7nXVEs720WHO14RwJVrxDO1zyqQQrD1At-d5Mp13-WqEMOE4YINDXIPH8H0FyW26xuMx9qU1xITHOVsPv378dGFtslsD7rzpe0jYmmBLmbMLy6LSx-XuKKalCdH12M5-mhM8R08H4zO8uK9H6Mu788-LD9XFp_cfF2cXlRW8bSrTMKZq1TadNaIZQA1EsY4IaWtlWW25rAUwY1rCeNtJ0tZCqppTRaWVwAU_Qm-3uqu5G6G3xVMyXq-KPZNudDROP54Ed6WXca1VzZRqWBE4vhdI8esMedKjyxa8NwHinDVjkigupdygr3fQ6zinUOwVqil_zouRQr36e6OHVf4EU4A3W8CmmHOC4QGhRG9C1yV0fRd6YU93WOsmM7m4MeP8_158cx5u_i2tF2eX2xe_AcYBvv4 |
| CitedBy_id | crossref_primary_10_1038_s41598_025_88621_0 crossref_primary_10_1007_s12094_019_02276_8 crossref_primary_10_1186_s13578_022_00866_8 crossref_primary_10_1016_j_biopha_2023_115079 crossref_primary_10_1016_j_actbio_2020_12_037 crossref_primary_10_3389_fvets_2023_1234628 crossref_primary_10_3390_ani12040516 crossref_primary_10_3389_fphar_2023_1243258 crossref_primary_10_1016_j_biopha_2021_112043 crossref_primary_10_3389_fimmu_2020_590618 crossref_primary_10_3389_fphar_2023_1159516 crossref_primary_10_1186_s42826_022_00128_1 crossref_primary_10_1002_vetr_1528 crossref_primary_10_1007_s10555_020_09930_6 crossref_primary_10_1016_j_mtbio_2021_100186 crossref_primary_10_1038_s41598_024_84297_0 crossref_primary_10_3389_fvets_2023_1032835 crossref_primary_10_3389_fmicb_2021_725074 crossref_primary_10_1186_s12915_023_01799_5 crossref_primary_10_3390_ani12182461 crossref_primary_10_1016_j_biopha_2023_114651 crossref_primary_10_1016_j_biomaterials_2020_119823 crossref_primary_10_3389_fimmu_2024_1290504 crossref_primary_10_3390_vetsci11100458 crossref_primary_10_1292_jvms_24_0344 crossref_primary_10_1016_j_biopha_2022_113105 crossref_primary_10_1002_VIW_20240073 crossref_primary_10_1002_ctm2_970 crossref_primary_10_3390_cancers13030422 crossref_primary_10_3390_cells12172188 crossref_primary_10_1016_j_ajpath_2024_04_009 crossref_primary_10_1186_s13567_021_00904_2 crossref_primary_10_1038_s41598_022_21706_2 crossref_primary_10_3390_ani11102770 crossref_primary_10_3390_cancers12040777 crossref_primary_10_1111_vco_12872 crossref_primary_10_1038_s41598_020_66229_w crossref_primary_10_1016_j_biopha_2022_113597 crossref_primary_10_3390_ijms221910763 crossref_primary_10_1016_j_actbio_2022_04_050 crossref_primary_10_1038_s41598_025_90623_x crossref_primary_10_3390_cells9010235 crossref_primary_10_1017_cts_2024_546 crossref_primary_10_1007_s13402_024_00960_8 crossref_primary_10_1186_s13059_023_03023_7 crossref_primary_10_3390_ani11072115 crossref_primary_10_1111_iju_14727 crossref_primary_10_3390_ijms25020701 crossref_primary_10_1007_s11356_021_15759_5 crossref_primary_10_1080_23808993_2020_1715794 crossref_primary_10_3389_fmedt_2022_895379 crossref_primary_10_1038_s41598_024_69070_7 crossref_primary_10_3390_pharmaceutics14122709 crossref_primary_10_3389_fonc_2023_1127448 crossref_primary_10_1186_s12917_023_03834_7 crossref_primary_10_3389_fonc_2022_855996 crossref_primary_10_1038_s41598_023_29065_2 crossref_primary_10_1007_s13402_023_00771_3 crossref_primary_10_3389_fvets_2021_779109 crossref_primary_10_3390_ijms222312891 crossref_primary_10_1080_15384047_2021_1919004 crossref_primary_10_3390_ijms23105453 crossref_primary_10_1002_ctd2_235 crossref_primary_10_3389_fonc_2023_1064548 crossref_primary_10_3390_ijms22179151 |
| Cites_doi | 10.1111/j.1939-1676.1990.tb00888.x 10.1038/sj.bjc.6602931 10.1002/stem.92 10.1111/j.1365-2885.2006.00725.x 10.1111/jvim.12533 10.1111/cas.13418 10.1201/9780367800130 10.3390/ijms19041098 10.1038/nrc1740 10.1016/j.fob.2013.06.004 10.1016/S0021-9975(05)80027-1 10.1111/jsap.12009 10.1016/S1078-1439(99)00006-X 10.1007/s00432-015-1972-8 10.1038/nrurol.2014.129 10.1136/vr.160.16.557 10.2460/javma.231.7.1056 10.1177/000348940211100816 10.1016/j.ccr.2014.01.009 10.1016/j.tvjl.2015.01.017 10.1007/s00280-015-2823-7 10.1046/j.1523-1747.1999.00546.x 10.1073/pnas.2034201100 10.1016/j.bbalip.2015.09.005 10.1016/j.jcpa.2006.07.002 10.1111/j.1476-5810.2005.00070.x 10.1186/1471-2407-11-200 10.1016/j.jchromb.2012.11.012 10.1080/07357900801941845 10.1136/vr.128.24.561 10.2460/javma.238.8.1004 10.1038/sj.bjc.6602298 10.1111/j.1939-1676.2003.tb02424.x 10.1111/j.1939-1676.1992.tb00330.x 10.1111/j.1939-1676.2011.00796.x 10.1158/1078-0432.CCR-05-0259 10.1158/1078-0432.CCR-13-3397 10.1091/mbc.E09-06-0451 10.1007/s00109-017-1531-7 10.1038/s41598-018-32698-3 10.1093/ilar/ilu018 10.1016/B978-1-4377-2362-5.00029-3 10.1146/annurev-pharmtox-010818-021108 10.3233/BLC-150044 10.1038/ncb2956 10.1016/S0378-1119(01)00360-2 10.1155/2016/7053872 10.1016/S0378-1119(01)00664-3 10.1097/MOU.0000000000000200 10.1111/j.1939-1676.1994.tb03232.x 10.1016/j.stem.2009.02.003 10.1007/s00403-013-1343-8 10.1007/s002800000147 10.1073/pnas.0906549106 10.1038/nrc3858 10.1515/BC.2003.099 10.1038/nature12965 10.3892/or.2017.5359 10.1091/mbc.E10-03-0261 |
| ContentType | Journal Article |
| Copyright | 2019 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2019. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2019 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2019. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1111/cas.14118 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine |
| DocumentTitleAlternate | ELBADAWY et al |
| EISSN | 1349-7006 |
| EndPage | 2821 |
| ExternalDocumentID | PMC6726682 31254429 10_1111_cas_14118 CAS14118 |
| Genre | article Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GrantInformation_xml | – fundername: Japan Society for the Promotion of Science funderid: 17K15370 – fundername: Japan Society for the Promotion of Science grantid: 17K15370 |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 24P 29B 2WC 31~ 36B 3O- 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7.U 702 7PT 8-0 8-1 8-3 8-4 8-5 8FE 8FH 8UM 930 A01 A03 AAHHS AAZKR ABCQN ABEML ACCFJ ACCMX ACSCC ACXQS ADBBV ADKYN ADPDF ADZMN ADZOD AEEZP AENEX AEQDE AFBPY AFEBI AFFNX AFKRA AFPKN AFZJQ AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BFHJK BHPHI BY8 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DIK DR2 DU5 E3Z EBS EJD EMB EMOBN EX3 F00 F01 F04 F5P FIJ GODZA GROUPED_DOAJ HCIFZ HF~ HOLLA HYE HZI HZ~ IAO IHR IPNFZ ITC IX1 J0M K.9 K48 KQ8 LC2 LC3 LH4 LK8 LP6 LP7 LW6 M7P MK4 N04 N05 N9A O9- OIG OK1 OVD P2P P2X P2Z P4B P4D PIMPY PROAC Q11 ROL RPM RX1 SJN SUPJJ SV3 TEORI UB1 W8V WIN WOW WQJ WRC WXI X7M XG1 ZXP ~IA ~WT 7X7 88E 8FI 8FJ AAFWJ AAYXX ABUWG CITATION FYUFA HMCUK M1P PHGZM PHGZT PSQYO UKHRP AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c4398-a82267698bca48fe6f062b045c76c27c3574e2aa90239b5097456731615c5e343 |
| IEDL.DBID | DR2 |
| ISSN | 1347-9032 1349-7006 |
| IngestDate | Thu Aug 21 14:33:09 EDT 2025 Fri Jul 11 08:08:03 EDT 2025 Wed Aug 13 03:52:42 EDT 2025 Mon Jul 21 05:52:49 EDT 2025 Tue Jul 01 01:31:06 EDT 2025 Thu Apr 24 23:03:13 EDT 2025 Wed Jan 22 16:38:41 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | RNA-seq biomarker dog bladder cancer organoid |
| Language | English |
| License | Attribution-NonCommercial 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4398-a82267698bca48fe6f062b045c76c27c3574e2aa90239b5097456731615c5e343 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Clinical Trial register and clinical registration number: 0016012 (Institute Animal Care and Use Committee of Tokyo University of Agriculture and Technology approval). Mohamed Elbadawy and Tatsuya Usui contributed equally to this work. |
| ORCID | 0000-0002-1818-2127 0000-0003-4251-1936 0000-0003-3417-9697 0000-0002-5239-8570 0000-0001-9368-1535 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.14118 |
| PMID | 31254429 |
| PQID | 2284293698 |
| PQPubID | 4378882 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6726682 proquest_miscellaneous_2250635552 proquest_journals_2284293698 pubmed_primary_31254429 crossref_primary_10_1111_cas_14118 crossref_citationtrail_10_1111_cas_14118 wiley_primary_10_1111_cas_14118_CAS14118 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | September 2019 |
| PublicationDateYYYYMMDD | 2019-09-01 |
| PublicationDate_xml | – month: 09 year: 2019 text: September 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Tokyo – name: Hoboken |
| PublicationTitle | Cancer science |
| PublicationTitleAlternate | Cancer Sci |
| PublicationYear | 2019 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
| References | 2001; 265 2015; 141 2013; 913–914 2013; 3 2011; 238 2000; 5 2000; 46 2002; 111 2015; 76 2014; 25 2011; 11 2003; 17 2016; 2016 2010; 140 2006; 135 2014; 20 1992; 6 2010; 21 2018; 8 2017; 37 2013; 54 2003; 9 2003; 2 2014; 16 2008; 26 2006; 29 2011; 25 2014; 55 2014; 11 2015; 15 2006; 94 2007; 160 2013; 305 2015; 1851 2006 1995; 113 2015; 205 1999; 5 2009; 27 2017; 95 2017; 108 2018; 19 1994; 8 2001; 275 2015; 25 2014; 507 2016; 2 2015; 29 2007; 231 1980; 54 2005; 5 2017 2005; 92 2005; 3 2013 2009; 4 1999; 112 1991; 128 2003; 100 2005; 11 2018; 59 2003; 384 1990; 4 2009; 106 e_1_2_8_24_1 Mohammed SI (e_1_2_8_40_1) 2003; 2 e_1_2_8_47_1 e_1_2_8_26_1 e_1_2_8_49_1 e_1_2_8_68_1 Conus S (e_1_2_8_57_1) 2010; 140 e_1_2_8_5_1 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_66_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_64_1 Henry CJ (e_1_2_8_15_1) 2003; 9 e_1_2_8_62_1 e_1_2_8_41_1 e_1_2_8_60_1 e_1_2_8_17_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_59_1 e_1_2_8_38_1 e_1_2_8_32_1 e_1_2_8_55_1 Knapp D (e_1_2_8_9_1) 2006 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_53_1 e_1_2_8_51_1 e_1_2_8_30_1 e_1_2_8_29_1 Priester WA (e_1_2_8_7_1) 1980; 54 e_1_2_8_25_1 e_1_2_8_46_1 e_1_2_8_27_1 e_1_2_8_48_1 e_1_2_8_2_1 e_1_2_8_4_1 e_1_2_8_6_1 e_1_2_8_8_1 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_67_1 e_1_2_8_44_1 e_1_2_8_65_1 e_1_2_8_63_1 Cozzi PJ (e_1_2_8_23_1) 1999; 5 e_1_2_8_61_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_16_1 e_1_2_8_37_1 e_1_2_8_58_1 Lerner SP (e_1_2_8_3_1) 2006 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_56_1 e_1_2_8_12_1 Meuten DJ (e_1_2_8_28_1) 2017 e_1_2_8_33_1 e_1_2_8_54_1 e_1_2_8_52_1 e_1_2_8_50_1 |
| References_xml | – volume: 29 start-page: 261 year: 2015 end-page: 267 article-title: Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first‐line treatment of urogenital tract transitional cell carcinoma in dogs publication-title: J Vet Intern Med – volume: 4 start-page: 148 year: 1990 end-page: 152 article-title: Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional cell carcinoma of the urinary bladder or urethra. A retrospective study of 15 dogs publication-title: J Vet Intern Med – volume: 128 start-page: 561 year: 1991 end-page: 565 article-title: Pharmacokinetics and pharmacodynamics of piroxicam in dogs publication-title: Vet Rec – volume: 8 start-page: 273 year: 1994 end-page: 278 article-title: Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder publication-title: J Vet Intern Med – volume: 3 start-page: 73 year: 2005 end-page: 80 article-title: Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder publication-title: Vet Comp Oncol – start-page: 665 year: 2017 end-page: 678 – volume: 5 start-page: 899 year: 2005 end-page: 904 article-title: Opinion: the origin of the cancer stem cell: current controversies and new insights publication-title: Nat Rev Cancer – volume: 507 start-page: 315 year: 2014 end-page: 322 article-title: Comprehensive molecular characterization of urothelial bladder carcinoma publication-title: Nature – volume: 238 start-page: 1004 year: 2011 end-page: 1010 article-title: Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder publication-title: J Am Vet Med Assoc – volume: 25 start-page: 152 year: 2014 end-page: 165 article-title: Identification of distinct basal and luminal subtypes of muscle‐invasive bladder cancer with different sensitivities to frontline chemotherapy publication-title: Cancer Cell – volume: 384 start-page: 883 year: 2003 end-page: 890 article-title: Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors publication-title: Biol Chem – volume: 6 start-page: 145 year: 1992 end-page: 153 article-title: Canine bladder and urethral tumors: a retrospective study of 115 cases (1980–1985) publication-title: J Vet Intern Med – volume: 5 start-page: 2629 year: 1999 end-page: 2637 article-title: Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs publication-title: Clin Cancer Res – start-page: 572 year: 2013 end-page: 582 – volume: 100 start-page: 11842 issue: Suppl 1 year: 2003 end-page: 11849 article-title: Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? publication-title: Proc Natl Acad Sci USA – volume: 11 start-page: 400 year: 2014 end-page: 410 article-title: Intrinsic basal and luminal subtypes of muscle‐invasive bladder cancer publication-title: Nat Rev Urol – volume: 112 start-page: 411 year: 1999 end-page: 418 article-title: Structure and function of hemidesmosomes: more than simple adhesion complexes publication-title: J Invest Dermatol – volume: 8 start-page: 14402 year: 2018 article-title: TFPI‐2 suppresses breast cancer cell proliferation and invasion through regulation of ERK signaling and interaction with actinin‐4 and myosin‐9 publication-title: Sci Rep – volume: 275 start-page: 185 year: 2001 end-page: 194 article-title: Promoter characterization of the human and mouse epilysin (MMP‐28) genes publication-title: Gene – volume: 11 start-page: 4415 year: 2005 end-page: 4429 article-title: Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder publication-title: Clin Cancer Res – volume: 15 start-page: 42 year: 2015 end-page: 54 article-title: Modelling bladder cancer in mice: opportunities and challenges publication-title: Nat Rev Cancer – volume: 16 start-page: 469 year: 2014 end-page: 478 article-title: Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma publication-title: Nat Cell Biol – volume: 29 start-page: 137 year: 2006 end-page: 145 article-title: Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics publication-title: J Vet Pharmacol Ther – volume: 305 start-page: 571 year: 2013 end-page: 584 article-title: Calponin 3 regulates stress fiber formation in dermal fibroblasts during wound healing publication-title: Arch Dermatol Res – volume: 21 start-page: 3973 year: 2010 end-page: 3984 article-title: Calponin 3 regulates actin cytoskeleton rearrangement in trophoblastic cell fusion publication-title: Mol Biol Cell – volume: 17 start-page: 136 year: 2003 end-page: 144 article-title: Canine transitional cell carcinoma publication-title: J Vet Intern Med – volume: 54 start-page: 1 year: 1980 end-page: 210 article-title: The occurrence of tumors in domestic animals publication-title: Natl Cancer Inst Monogr – volume: 108 start-page: 2383 year: 2017 end-page: 2392 article-title: Establishment of a dog primary prostate cancer organoid using the urine cancer stem cells publication-title: Cancer Sci – volume: 106 start-page: 14016 year: 2009 end-page: 14021 article-title: Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor‐initiating cells publication-title: Proc Natl Acad Sci USA – volume: 11 start-page: 200 year: 2011 article-title: MMP28 (epilysin) as a novel promoter of invasion and metastasis in gastric cancer publication-title: BMC Cancer – volume: 5 start-page: 47 year: 2000 end-page: 59 article-title: Naturally‐occurring canine transitional cell carcinoma of the urinary bladder A relevant model of human invasive bladder cancer publication-title: Urol Oncol – volume: 37 start-page: 1100 year: 2017 end-page: 1106 article-title: Death‐associated protein kinase 3 controls the tumor progression of A549 cells through ERK MAPK/c‐Myc signaling publication-title: Oncol Rep – volume: 205 start-page: 217 year: 2015 end-page: 225 article-title: Management of transitional cell carcinoma of the urinary bladder in dogs: a review publication-title: Vet J – volume: 59 start-page: 447 year: 2018 end-page: 462 article-title: Organoids for drug discovery and personalized medicine publication-title: Annu Rev Pharmacol Toxicol – volume: 9 start-page: 906 year: 2003 article-title: Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma publication-title: Clin Cancer Res – volume: 913–914 start-page: 147 year: 2013 end-page: 154 article-title: Simultaneous quantification of vinblastine and desacetylvinblastine concentrations in canine plasma and urine samples using LC‐APCI‐MS/MS publication-title: J Chromatogr B Analyt Technol Biomed Life Sci – volume: 135 start-page: 190 year: 2006 end-page: 199 article-title: Classification of canine urinary bladder urothelial tumours based on the World Health Organization/International Society of Urological Pathology consensus classification publication-title: J Comp Pathol – volume: 111 start-page: 745 year: 2002 end-page: 750 article-title: Cisplatin‐induced ototoxicity and pharmacokinetics: preliminary findings in a dog model publication-title: Ann Otol Rhinol Laryngol – volume: 19 start-page: 1098 year: 2018 article-title: Hedgehog signals mediate anti‐cancer drug resistance in three‐dimensional primary colorectal cancer organoid culture publication-title: Int J Mol Sci – volume: 265 start-page: 87 year: 2001 end-page: 93 article-title: MMP‐28, a new human matrix metalloproteinase with an unusual cysteine‐switch sequence is widely expressed in tumors publication-title: Gene – volume: 27 start-page: 1487 year: 2009 end-page: 1495 article-title: Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma publication-title: Stem Cells – volume: 92 start-page: 775 year: 2005 end-page: 783 article-title: Expression and methylation status of tissue factor pathway inhibitor‐2 gene in non‐small‐cell lung cancer publication-title: Br J Cancer – volume: 55 start-page: 100 year: 2014 end-page: 118 article-title: Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development publication-title: ILAR J – volume: 94 start-page: 569 year: 2006 end-page: 577 article-title: Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma publication-title: Br J Cancer – volume: 76 start-page: 525 year: 2015 end-page: 536 article-title: In vivo pharmacokinetic and tissue distribution investigation of sustained‐release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs publication-title: Cancer Chemother Pharmacol – volume: 25 start-page: 1385 year: 2011 end-page: 1390 article-title: Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder publication-title: J Vet Intern Med – volume: 26 start-page: 725 year: 2008 end-page: 733 article-title: Bladder cancer initiating cells (BCICs) are among EMA‐CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells publication-title: Cancer Invest – volume: 21 start-page: 1409 year: 2010 end-page: 1422 article-title: h3/Acidic calponin: an actin‐binding protein that controls extracellular signal‐regulated kinase 1/2 activity in nonmuscle cells publication-title: Mol Biol Cell – volume: 2016 start-page: 1 year: 2016 end-page: 10 article-title: Establishment of a novel model for anticancer drug resistance in three‐dimensional primary culture of tumor microenvironment publication-title: Stem Cells Int – volume: 46 start-page: 221 year: 2000 end-page: 226 article-title: Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer publication-title: Cancer Chemother Pharmacol – volume: 231 start-page: 1056 year: 2007 end-page: 1060 article-title: Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder publication-title: J Am Vet Med Assoc – volume: 160 start-page: 557 year: 2007 end-page: 558 article-title: Recurrent and metastatic canine urethral transitional cell carcinoma without bladder involvement publication-title: Vet Rec – volume: 141 start-page: 2097 year: 2015 end-page: 2107 article-title: Hypermethylation of ITGA4, TFPI2 and VIMENTIN promoters is increased in inflamed colon tissue: putative risk markers for colitis‐associated cancer publication-title: J Cancer Res Clin Oncol – volume: 20 start-page: 4001 year: 2014 end-page: 4013 article-title: BCMab1, a monoclonal antibody against aberrantly glycosylated integrin alpha3 beta1, has potent antitumor activity of bladder cancer in vivo publication-title: Clin Cancer Res – volume: 3 start-page: 291 year: 2013 end-page: 301 article-title: Beneficial role of overexpression of TFPI‐2 on tumour progression in human small cell lung cancer publication-title: FEBS Open Bio – volume: 95 start-page: 729 year: 2017 end-page: 738 article-title: Stem cell‐derived organoids and their application for medical research and patient treatment publication-title: J Mol Med (Berl) – volume: 54 start-page: 67 year: 2013 end-page: 74 article-title: Retrospective evaluation of doxorubicin‐piroxicam combination for the treatment of transitional cell carcinoma in dogs publication-title: J Small Anim Pract – volume: 25 start-page: 449 year: 2015 end-page: 458 article-title: Genetic subtypes of invasive bladder cancer publication-title: Curr Opin Urol – year: 2006 – volume: 113 start-page: 113 year: 1995 end-page: 130 article-title: Pathology of canine bladder and urethral cancer and correlation with tumour progression and survival publication-title: J Comp Pathol – volume: 2 start-page: 183 year: 2003 end-page: 188 article-title: Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer publication-title: Mol Cancer Ther – volume: 140 start-page: w13042 year: 2010 article-title: Cathepsins and their involvement in immune responses publication-title: Swiss Med Wkly – start-page: 171 year: 2006 end-page: 175 – volume: 1851 start-page: 1566 year: 2015 end-page: 1576 article-title: Acylglycerophosphate acyltransferase 4 (AGPAT4) is a mitochondrial lysophosphatidic acid acyltransferase that regulates brain phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol levels publication-title: Biochem Biophys Acta – volume: 4 start-page: 203 year: 2009 end-page: 205 article-title: Cancer stem cells: controversial or just misunderstood? publication-title: Cell Stem Cell – volume: 2 start-page: 241 year: 2016 end-page: 250 article-title: A nonselective cyclooxygenase inhibitor enhances the activity of vinblastine in a naturally‐occurring canine model of invasive urothelial carcinoma publication-title: Bladder Cancer – year: 2013 – ident: e_1_2_8_37_1 doi: 10.1111/j.1939-1676.1990.tb00888.x – start-page: 665 volume-title: Tumors in Domestic Animals year: 2017 ident: e_1_2_8_28_1 – volume: 140 start-page: w13042 year: 2010 ident: e_1_2_8_57_1 article-title: Cathepsins and their involvement in immune responses publication-title: Swiss Med Wkly – ident: e_1_2_8_67_1 doi: 10.1038/sj.bjc.6602931 – start-page: 171 volume-title: Textbook of Bladder Cancer year: 2006 ident: e_1_2_8_9_1 – ident: e_1_2_8_50_1 doi: 10.1002/stem.92 – ident: e_1_2_8_22_1 doi: 10.1111/j.1365-2885.2006.00725.x – ident: e_1_2_8_33_1 doi: 10.1111/jvim.12533 – ident: e_1_2_8_18_1 doi: 10.1111/cas.13418 – volume-title: Textbook of Bladder Cancer year: 2006 ident: e_1_2_8_3_1 doi: 10.1201/9780367800130 – volume: 9 start-page: 906 year: 2003 ident: e_1_2_8_15_1 article-title: Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma publication-title: Clin Cancer Res – ident: e_1_2_8_20_1 doi: 10.3390/ijms19041098 – ident: e_1_2_8_46_1 doi: 10.1038/nrc1740 – ident: e_1_2_8_62_1 doi: 10.1016/j.fob.2013.06.004 – ident: e_1_2_8_5_1 doi: 10.1016/S0021-9975(05)80027-1 – ident: e_1_2_8_32_1 doi: 10.1111/jsap.12009 – ident: e_1_2_8_11_1 doi: 10.1016/S1078-1439(99)00006-X – ident: e_1_2_8_64_1 doi: 10.1007/s00432-015-1972-8 – ident: e_1_2_8_47_1 doi: 10.1038/nrurol.2014.129 – ident: e_1_2_8_13_1 doi: 10.1136/vr.160.16.557 – ident: e_1_2_8_30_1 doi: 10.2460/javma.231.7.1056 – ident: e_1_2_8_25_1 doi: 10.1177/000348940211100816 – ident: e_1_2_8_34_1 doi: 10.1016/j.ccr.2014.01.009 – ident: e_1_2_8_36_1 doi: 10.1016/j.tvjl.2015.01.017 – ident: e_1_2_8_26_1 doi: 10.1007/s00280-015-2823-7 – ident: e_1_2_8_65_1 doi: 10.1046/j.1523-1747.1999.00546.x – ident: e_1_2_8_44_1 doi: 10.1073/pnas.2034201100 – ident: e_1_2_8_66_1 doi: 10.1016/j.bbalip.2015.09.005 – ident: e_1_2_8_4_1 doi: 10.1016/j.jcpa.2006.07.002 – ident: e_1_2_8_41_1 doi: 10.1111/j.1476-5810.2005.00070.x – ident: e_1_2_8_54_1 doi: 10.1186/1471-2407-11-200 – ident: e_1_2_8_24_1 doi: 10.1016/j.jchromb.2012.11.012 – ident: e_1_2_8_51_1 doi: 10.1080/07357900801941845 – ident: e_1_2_8_21_1 doi: 10.1136/vr.128.24.561 – ident: e_1_2_8_31_1 doi: 10.2460/javma.238.8.1004 – ident: e_1_2_8_61_1 doi: 10.1038/sj.bjc.6602298 – volume: 5 start-page: 2629 year: 1999 ident: e_1_2_8_23_1 article-title: Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs publication-title: Clin Cancer Res – ident: e_1_2_8_8_1 doi: 10.1111/j.1939-1676.2003.tb02424.x – ident: e_1_2_8_12_1 doi: 10.1111/j.1939-1676.1992.tb00330.x – ident: e_1_2_8_39_1 doi: 10.1111/j.1939-1676.2011.00796.x – ident: e_1_2_8_68_1 doi: 10.1158/1078-0432.CCR-05-0259 – ident: e_1_2_8_52_1 doi: 10.1158/1078-0432.CCR-13-3397 – ident: e_1_2_8_58_1 doi: 10.1091/mbc.E09-06-0451 – ident: e_1_2_8_16_1 doi: 10.1007/s00109-017-1531-7 – ident: e_1_2_8_63_1 doi: 10.1038/s41598-018-32698-3 – ident: e_1_2_8_14_1 doi: 10.1093/ilar/ilu018 – ident: e_1_2_8_6_1 doi: 10.1016/B978-1-4377-2362-5.00029-3 – ident: e_1_2_8_17_1 doi: 10.1146/annurev-pharmtox-010818-021108 – ident: e_1_2_8_42_1 doi: 10.3233/BLC-150044 – ident: e_1_2_8_43_1 doi: 10.1038/ncb2956 – ident: e_1_2_8_53_1 doi: 10.1016/S0378-1119(01)00360-2 – ident: e_1_2_8_19_1 doi: 10.1155/2016/7053872 – ident: e_1_2_8_55_1 doi: 10.1016/S0378-1119(01)00664-3 – ident: e_1_2_8_48_1 doi: 10.1097/MOU.0000000000000200 – ident: e_1_2_8_38_1 doi: 10.1111/j.1939-1676.1994.tb03232.x – ident: e_1_2_8_45_1 doi: 10.1016/j.stem.2009.02.003 – ident: e_1_2_8_2_1 doi: 10.1016/B978-1-4377-2362-5.00029-3 – ident: e_1_2_8_59_1 doi: 10.1007/s00403-013-1343-8 – ident: e_1_2_8_29_1 doi: 10.1007/s002800000147 – ident: e_1_2_8_49_1 doi: 10.1073/pnas.0906549106 – ident: e_1_2_8_10_1 doi: 10.1038/nrc3858 – ident: e_1_2_8_56_1 doi: 10.1515/BC.2003.099 – volume: 2 start-page: 183 year: 2003 ident: e_1_2_8_40_1 article-title: Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer publication-title: Mol Cancer Ther – ident: e_1_2_8_35_1 doi: 10.1038/nature12965 – ident: e_1_2_8_27_1 doi: 10.3892/or.2017.5359 – volume: 54 start-page: 1 year: 1980 ident: e_1_2_8_7_1 article-title: The occurrence of tumors in domestic animals publication-title: Natl Cancer Inst Monogr – ident: e_1_2_8_60_1 doi: 10.1091/mbc.E10-03-0261 |
| SSID | ssj0036494 |
| Score | 2.5233355 |
| Snippet | In human and dogs, bladder cancer (BC) is the most common neoplasm affecting the urinary tract. Dog BC resembles human muscle‐invasive BC in histopathological... In human and dogs, bladder cancer ( BC ) is the most common neoplasm affecting the urinary tract. Dog BC resembles human muscle‐invasive BC in... In human and dogs, bladder cancer (BC) is the most common neoplasm affecting the urinary tract. Dog BC resembles human muscle-invasive BC in histopathological... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2806 |
| SubjectTerms | Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antineoplastic drugs Antitumor agents biomarker Biomarkers Biomarkers, Tumor - analysis Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Bladder cancer Cancer therapies Cell adhesion & migration Cell culture Cell Culture Techniques - methods Cell Line, Tumor Cell Survival - drug effects Cell viability Chemotherapy Cisplatin Desmoglein 3 dog Dog Diseases - drug therapy Dog Diseases - genetics Dog Diseases - pathology Dog Diseases - urine Dogs Female Gemcitabine Gene expression Gene Expression Profiling Gene Expression Regulation, Neoplastic Invasiveness Laboratory animals Male Medical prognosis Metastasis Neoplasia organoid Organoids Organoids - drug effects Organoids - metabolism Organoids - pathology Original Piroxicam Principal components analysis Prostate cancer Ribonucleic acid RNA RNA‐seq Sequence Analysis, RNA Smooth muscle Stem cells Tumorigenesis Up-Regulation Urinary Bladder - cytology Urinary Bladder - pathology Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - urine Urinary Bladder Neoplasms - veterinary Urinary tract Urine Urine - cytology Urothelium - cytology Veterinary medicine Vinblastine |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BkRAXBMsrUJBBHHqJSPxI7BOqqlYVUrlA0d4ix3HKSktSdrs9ceAn8Bv5Jcw4TthS4BbFlvOY8fjLePJ9AK-tNU2jrUy1MjyVprYp4eTUySbTzirdhFT2yfvi-FS-m6t5TLitY1nlGBNDoG56RznyNxzjKCf1Of32_GtKqlG0uxolNG7CLaIuI68u59MHlyikGURtZZmaTPDILESVPCQolsuctD6216NrIPN6reQ2hg2L0NE9uBvRI9sfzH0fbvhuBrdP4v74DGafqLol_GLLxrMP4NshQsCQbaJUIOtbZlnXX_ol2-b3Z0EUhyGIZV82axz-5_cfi-7SUn07q5cUoVbMkZOsGFXLn-EoTX_2Z1OQieoXDRs4PfxDOD06_HhwnEbVBbSPMDq1CBmo7lXXRHje-qLNCl4j8nNl4XjphCql52hj-i22RrxRIgYj_atcOeWFFI9gp-s7_wSY4JkrMGJoVQtZ28y0WhrbcsPbvFAuT2BvfPeVi5TkpIyxrMZPEzRTFcyUwKup6_nAw_G3TrujAas4FdfVb8dJ4OXUjJOIdkZs5_sN9VEZIS_FE3g82Hu6isiJxY2bBMornjB1IILuqy3d4nMg6i5KhD8ax9wLPvPvG68O9j-Eg6f_f4JncAcBW6xx24Wdi9XGP0dQdFG_CJ7_C-tpDFY priority: 102 providerName: ProQuest |
| Title | Establishment of a novel experimental model for muscle‐invasive bladder cancer using a dog bladder cancer organoid culture |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.14118 https://www.ncbi.nlm.nih.gov/pubmed/31254429 https://www.proquest.com/docview/2284293698 https://www.proquest.com/docview/2250635552 https://pubmed.ncbi.nlm.nih.gov/PMC6726682 |
| Volume | 110 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9VAEB5qBfHF-yVaD6v40JeUZC9JFp9qOaUILaVaOA9C2N0k9eAxkXPpg_jgT_A3-kuc2Vw4p1UQX0JgJ7ub7Mzsl8nkG4DXxuiiyIwMM6V5KLU1IeHk0MkiypxRWeFD2ccnydG5fDdRky140_8L0_JDDAE3sgzvr8nAjV2sGTmVBIsl4mP0v5SrRYDobKCOEonUbUFbmYY6ErxjFaIsnuHKzb3oGsC8nie5jl_9BnR4Fz72U2_zTj7vrZZ2z327wur4n_d2D-50wJTtt5p0H7bK-gHcOu4-vT-E72PEkT5kRfFE1lTMsLq5LGdsvUgA85V1GCJh9mW1wI5-_fg5rS8NJckzOyM3N2eONG3OKOX-AnspmourTb7WVDMtWEsMUj6C88Pxh4OjsCvdgIssdBYaxB2UPJtZYk2vyqSKEm4RPro0cTx1QqWy5Kgo9G-tRdCSIpCjIlqxcqoUUjyG7bqpy6fABI9cgm4nU1ZIayJdZVKbimtexYlycQC7_SLmruM1p_Ias7x_v8GnmfunGcCrQfRrS-bxJ6GdXhPyzp4XOQ6PG7fAGwrg5dCMlkifV0xdNiuSURHBN8UDeNIqzjCKiIkKjusA0g2VGgSI5XuzpZ5-8mzfSYoYKsM-d73G_H3i-cH-e3_y7N9Fn8NtRIBd0twObC_nq_IFoqylHcENLk_xmE7SEdx8Oz45PRv5iMXIG9pvCiEo4w |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB6VIgEXBMtfoIBBIPUSkTh2Eh8QqkqrLe32Qov2FhzHKSstSdntFiFx4BF4Eh6KJ2HG-WFLgVtvUWzZcWY889kezwfwTGtVFKkWfioV94XKtU842TeiCFKjZVq4rezRfjw8FG_GcrwCP7q7MBRW2dlEZ6iL2tAe-QuOdpQT-1z66viTT6xRdLraUWg0arFrv3zGJdv85c5rlO9zzre3DjaHfssqgP1HKvU1ukSK60xzSuhd2rgMYp4jsjFJbHhiIpkIy3EMdO0zR3-aIMYgfqdQGmkjEWG7l-AyOt6AFnvJuF_gRbFQDYmuSHwVRLzNZESRQ0RgFoqQuEWW_d85UHs-NnMZMzunt30DrrdolW006nUTVmw1gCuj9jx-AIN3FE3jrvSy7u0t-LqFkNPtbtHWI6tLpllVn9opW-YTYI6EhyFoZh8Xc2z-57fvk-pUUzw9y6dkEWfMkFLOGEXnH2ErRX30Z5GjpaonBWtyiNjbcHgh8rgDq1Vd2XvAIh6YGC1UKvNI5DpQZSqULrniZRhLE3qw3v37zLQp0ImJY5p1SyEUU-bE5MHTvupxk_fjb5XWOgFm7dSfZ78V1YMnfTFOWjqJ0ZWtF1RHBoT0JPfgbiPvvpcopKxxXHmQnNGEvgIlBD9bUk0-uMTgcYJwK8U2153O_PvDs82Nt-7h_v9H8BiuDg9Ge9nezv7uA7iGYLGNr1uD1ZPZwj5EQHaSP3KzgMH7i552vwBoZEX7 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFD4anTRxg6D8FQYYBNJuoiWOndgXCI2t1cZYNQFDu8scJxmVSjLadQiJCx6B5-FxeBLOcZLSMeBud1VtuUnP8Tmf7c_nA3hqjM4yZYSnpOae0KnxCCd7VmS-skaqzG1l7w2j7QPx6lAeLsGP9i4M0SrbmOgCdVZZ2iNf5xhHOanPqfWioUXsbw1enHzySEGKTlpbOY3aRXbzL59x-TZ9vrOFtn7G-aD_bnPbaxQG8FlCrTyD6ZE4niql4t5FHhV-xFNEOTaOLI9tKGORc3wfugKaYm6NEW-Q1lMgrcxDEeK4V2A5plVRB5Zf9of7b9o8EEZC15K6Iva0H_KmrhHxiEjOLBABKY0sZsMLEPciU3MRQbsUOLgO1xrsyjZqZ7sBS3nZhZW95nS-C933xK1xF3xZ--1N-NpHAOr2umgjklUFM6yszvIxW1QXYE6ShyGEZh9nUxz-57fvo_LMELuepWOKjxNmyUUnjLj6xzhKVh3_2eREqqpRxuqKIvktOLgUi9yGTlmV-V1gIfdthPFKyTQUqfF1oYQ2Bde8CCJpgx6stf99YpuC6KTLMU7ahRGaKXFm6sGTedeTugrI3zqttgZMmkAwTX67bQ8ez5txCtO5jCnzakZ9pE-4T_Ie3KntPf-VMKAaclz3ID7nCfMOVB78fEs5-uDKhEcxgi-FY645n_n3gyebG2_dh3v_f4NHsIJTLnm9M9y9D1cROTZku1XonE5m-QNEZ6fpw2YaMDi67Jn3C0GzS5Y |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Establishment+of+a+novel+experimental+model+for+muscle-invasive+bladder+cancer+using+a+dog+bladder+cancer+organoid+culture&rft.jtitle=Cancer+science&rft.au=Elbadawy%2C+Mohamed&rft.au=Usui%2C+Tatsuya&rft.au=Mori%2C+Takashi&rft.au=Tsunedomi%2C+Ryouichi&rft.date=2019-09-01&rft.issn=1349-7006&rft.eissn=1349-7006&rft.volume=110&rft.issue=9&rft.spage=2806&rft_id=info:doi/10.1111%2Fcas.14118&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon |